Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial

Affiliations

Comment

Hyon K Choi et al. Arthritis Rheumatol. 2021 May.

. 2021 May;73(5):721-724.

doi: 10.1002/art.41638. Epub 2021 Mar 8.

No abstract available

Comment on

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Clinical Trial.
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Clinical Trial.

1. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200–10. - PubMed
1. US Food and Drug Administration. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat): FDA drug safety communication. February 2019. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-wa....
1. Kim SC, Neogi T, Kim E, Lii J, Desai RJ. Trends in utilization of urate-lowering therapies following the US Food and Drug Administration’s boxed warning on febuxostat. Arthritis Rheumatol 2021;73:542–3. - PMC - PubMed
1. Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020;396:1745–57. - PubMed
1. Choi H, Neogi T, Stamp L, Dalbeth N, Terkeltaub R. Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities trial and the associated Food and Drug Administration public safety alert. Arthritis Rheumatol 2018;70:1702–9. - PMC - PubMed